Monopar Therapeutics Files 8-K

Ticker: MNPR · Form: 8-K · Filed: 2024-10-15T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 8-k, disclosure

Related Tickers: MNPR

TL;DR

Monopar Therapeutics filed an 8-K today, likely containing important updates for investors.

AI Summary

On October 15, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates that Monopar Therapeutics is providing updates or disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific financial or operational details that would indicate a high risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Monopar Therapeutics?

The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.

On what date was the earliest event reported in this filing?

The earliest event reported was on October 15, 2024.

In which state is Monopar Therapeutics incorporated?

Monopar Therapeutics Inc. is incorporated in Delaware.

What is the principal executive office address for Monopar Therapeutics?

The principal executive office is located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.

Does the filing excerpt mention any specific financial results or material events?

No, the provided excerpt does not detail specific financial figures or material events.

From the Filing

0001437749-24-031184.txt : 20241015 0001437749-24-031184.hdr.sgml : 20241015 20241015080009 ACCESSION NUMBER: 0001437749-24-031184 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20241015 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241015 DATE AS OF CHANGE: 20241015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 241369335 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20241014_8k.htm FORM 8-K mnpr20241014_8k.htm false 0001645469 0001645469 2024-10-15 2024-10-15     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): October 15, 2024   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd. , Suite 350 , Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒           Item 7.01   Regulation FD Disclosure.     On October 15, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing it has filed a provisional patent application pertaining to therapeutic radiopharmaceuticals based on a family of linkers used to connect radioisotpes with targeting agents.   The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.   Item 9.01 Financial Statements and Exhibits   Exhibit No.      Description 99.1   Press Release Dated October 15, 2024 104   Cover Page Interactive Data File (embedded w

View on Read The Filing